SGMO Sangamo Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: SGMO
Price (delayed)
$0.53
Market cap
$159.91M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.29
Enterprise value
$143.52M
Sangamo Therapeutics is committed to translating ground-breaking science into genomic medicines with the potential to transform patients' lives using gene therapy, cell therapy, and genome engineering.
Highlights
The EPS has surged by 79% year-on-year and by 26% since the previous quarter
Sangamo Therapeutics's net income has surged by 75% YoY and by 20% QoQ
The equity fell by 17% YoY
Key stats
What are the main financial stats of SGMO
Market
Valuations
Earnings
Shares outstanding
301.71M
Market cap
$159.91M
Enterprise value
$143.52M
Price to earnings (P/E)
N/A
Price to book (P/B)
6.3
Price to sales (P/S)
1.67
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.76
Revenue
$81.71M
Gross profit
$81.71M
Operating income
-$62.84M
Net income
-$63.31M
EBIT
-$63.5M
EBITDA
-$55.42M
Free cash flow
-$36.19M
Per share
Balance sheet
Liquidity
EPS
-$0.29
EPS diluted
-$0.3
Free cash flow per share
-$0.14
Book value per share
$0.08
Revenue per share
$0.32
TBVPS
$0.38
Total assets
$97.56M
Total liabilities
$77.96M
Debt
$23.46M
Equity
$19.6M
Working capital
$2.23M
Debt to equity
1.2
Current ratio
1.05
Quick ratio
0.84
Net debt/EBITDA
0.3
Margins
Efficiency
Dividend
EBITDA margin
-67.8%
Gross margin
100%
Net margin
-77.5%
Operating margin
-76.9%
Return on assets
-65.1%
Return on equity
-299%
Return on invested capital
-156.7%
Return on capital employed
-127.3%
Return on sales
-77.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
SGMO stock price
How has the Sangamo Therapeutics stock price performed over time
Intraday
20.35%
1 week
0%
1 month
7.72%
1 year
-51.82%
YTD
-48.04%
QTD
-2.09%
Financial performance
How have Sangamo Therapeutics's revenue and profit performed over time
Revenue
$81.71M
Gross profit
$81.71M
Operating income
-$62.84M
Net income
-$63.31M
Gross margin
100%
Net margin
-77.5%
SGMO's operating margin has surged by 96% year-on-year and by 40% since the previous quarter
SGMO's net margin has soared by 96% YoY and by 38% QoQ
The operating income has soared by 76% YoY and by 23% from the previous quarter
Sangamo Therapeutics's net income has surged by 75% YoY and by 20% QoQ
Price vs fundamentals
How does SGMO's price correlate with its fundamentals
Growth
What is Sangamo Therapeutics's growth rate over time
Valuation
What is Sangamo Therapeutics stock price valuation
P/E
N/A
P/B
6.3
P/S
1.67
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.76
The EPS has surged by 79% year-on-year and by 26% since the previous quarter
The price to book (P/B) is 58% lower than the last 4 quarters average of 12.6 but 19% higher than the 5-year quarterly average of 4.4
The equity fell by 17% YoY
The stock's P/S is 78% below its 5-year quarterly average of 6.3 and 49% below its last 4 quarters average of 2.7
The revenue is up by 28% since the previous quarter
Efficiency
How efficient is Sangamo Therapeutics business performance
The return on sales has surged by 96% year-on-year and by 38% since the previous quarter
The company's return on assets has surged by 60% YoY and by 21% QoQ
Sangamo Therapeutics's return on invested capital has increased by 41% YoY and by 9% QoQ
The ROE has grown by 16% from the previous quarter and by 11% YoY
Dividends
What is SGMO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for SGMO.
Financial health
How did Sangamo Therapeutics financials performed over time
SGMO's total assets is 25% greater than its total liabilities
The quick ratio has surged by 53% since the previous quarter and by 15% year-on-year
The company's current ratio rose by 38% QoQ
SGMO's debt is 20% higher than its equity
Sangamo Therapeutics's debt to equity has shrunk by 76% QoQ and by 2.4% YoY
SGMO's debt is down by 19% YoY and by 6% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.